Share Price and Basic Stock Data
Last Updated: November 15, 2025, 10:52 pm
| PEG Ratio | 0.12 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Cravatex Ltd operates primarily in the trading and distribution industry, with a market capitalization of ₹105 Cr and a share price of ₹406. The company has shown fluctuating revenue trends, with total sales reporting ₹504 Cr for the fiscal year ending March 2023, a decline from ₹594 Cr in FY 2022. The quarterly revenue figures indicate a consistent downward trajectory, with a notable drop to ₹56.60 Cr in June 2023, followed by a slight increase to ₹57.45 Cr in September 2023. However, projections for subsequent quarters remain weak, as sales figures for March 2024 and beyond suggest continued challenges, with reported sales of ₹203 Cr for FY 2024 and ₹174 Cr for FY 2025. This decline raises concerns about the company’s ability to stabilize its revenue streams in a competitive market.
Profitability and Efficiency Metrics
Cravatex Ltd’s profitability metrics reflect significant challenges, with an operating profit margin (OPM) reported at -26.42% for June 2025, indicating ongoing operational inefficiencies. The company has consistently struggled with negative operating profits across multiple quarters, culminating in an operating loss of ₹30 Cr for FY 2023. Despite a brief positive operating profit of ₹0.18 Cr in June 2023, subsequent quarters again reported losses. The interest coverage ratio stood at 20.39x, suggesting that the company can comfortably meet its interest obligations despite its lack of borrowings, which remained at ₹0 Cr. Return on equity (ROE) has hovered around 4.68%, while return on capital employed (ROCE) was recorded at 6.57%, both of which fall below typical sector averages, indicating limited efficiency in utilizing shareholder funds and capital.
Balance Sheet Strength and Financial Ratios
Cravatex Ltd’s balance sheet exhibits notable strengths, particularly in liquidity and leverage. The current ratio is a robust 4.22x, and the quick ratio is 3.86x, indicating strong short-term financial health. The absence of any borrowings (₹0 Cr) underscores a debt-free position, allowing for flexibility in financial operations. The company reported reserves of ₹104 Cr, marking a steady increase from ₹90 Cr in FY 2023. However, the price-to-book value ratio at 0.83x suggests that the stock is trading below its book value, reflecting potential undervaluation or investor skepticism regarding future growth prospects. Additionally, the enterprise value (EV) to net operating revenue ratio of 0.07x indicates that the market may not fully recognize the company’s revenue-generating potential.
Shareholding Pattern and Investor Confidence
Cravatex Ltd has a stable shareholding pattern, with promoters holding a significant 75% stake in the company, reflecting strong control and commitment to the business. The public shareholding accounts for 25%, with the total number of shareholders increasing to 2,456 as of September 2025, which can be interpreted as a positive sign of growing investor interest. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may indicate a lack of confidence from larger institutional players, potentially impacting the stock’s liquidity and overall market perception. The company’s dividend payout percentage has fluctuated, with a payout of 67% projected for FY 2025, which may attract income-focused investors despite the overall profitability challenges.
Outlook, Risks, and Final Insight
Cravatex Ltd faces a challenging outlook characterized by declining revenue and profitability metrics, which may hinder its growth trajectory. The significant drop in sales and persistent operational losses present considerable risks, including the potential for cash flow pressures in the coming fiscal periods. Moreover, the company’s reliance on trading and distribution exposes it to market volatility and competition, which could further strain revenue streams. However, its strong liquidity position and absence of debt provide a buffer against short-term financial distress. Moving forward, the company must implement effective strategies to enhance operational efficiency, stabilize revenue, and regain investor confidence. Achievements in these areas could lead to a more favorable assessment from the market, while failure to address these challenges may result in continued underperformance and diminished shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Cravatex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minal Industries Ltd | 68.9 Cr. | 3.59 | 5.59/3.20 | 45.9 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 12.6 Cr. | 14.3 | 18.6/13.0 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 6.37 Cr. | 70.0 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 93.7 Cr. | 45.7 | 49.8/10.2 | 92.8 | 15.0 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| MRP Agro Ltd | 107 Cr. | 96.0 | 174/84.4 | 15.1 | 30.6 | 0.00 % | 39.2 % | 30.3 % | 10.0 |
| Industry Average | 11,409.25 Cr | 164.48 | 101.45 | 117.47 | 0.39% | 15.44% | 8.88% | 7.74 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 162.40 | 170.42 | 87.10 | 83.74 | 56.60 | 57.45 | 37.90 | 50.68 | 25.78 | 55.04 | 32.43 | 60.52 | 23.13 |
| Expenses | 166.43 | 176.91 | 103.63 | 87.03 | 56.42 | 59.62 | 41.69 | 52.56 | 28.11 | 53.03 | 34.30 | 60.01 | 29.24 |
| Operating Profit | -4.03 | -6.49 | -16.53 | -3.29 | 0.18 | -2.17 | -3.79 | -1.88 | -2.33 | 2.01 | -1.87 | 0.51 | -6.11 |
| OPM % | -2.48% | -3.81% | -18.98% | -3.93% | 0.32% | -3.78% | -10.00% | -3.71% | -9.04% | 3.65% | -5.77% | 0.84% | -26.42% |
| Other Income | 1.50 | 2.52 | 107.57 | 6.59 | 1.58 | 6.03 | 5.82 | 2.68 | 3.48 | 2.14 | 2.24 | 2.09 | 5.21 |
| Interest | 3.69 | 4.86 | 3.51 | 1.31 | 0.08 | 0.08 | 0.13 | 0.11 | 0.11 | 0.11 | 0.11 | 0.09 | 0.09 |
| Depreciation | 3.94 | 8.85 | 2.91 | 0.44 | 0.47 | 0.53 | 0.49 | 0.39 | 0.34 | 0.34 | 0.40 | 0.40 | 0.38 |
| Profit before tax | -10.16 | -17.68 | 84.62 | 1.55 | 1.21 | 3.25 | 1.41 | 0.30 | 0.70 | 3.70 | -0.14 | 2.11 | -1.37 |
| Tax % | 9.25% | 8.54% | -0.90% | -147.74% | 64.46% | 4.00% | 43.97% | -70.00% | 30.00% | 28.38% | -278.57% | 31.75% | 0.73% |
| Net Profit | -11.11 | -19.18 | 85.38 | 3.84 | 0.42 | 3.11 | 0.79 | 0.50 | 0.48 | 2.65 | 0.25 | 1.44 | -1.37 |
| EPS in Rs | -42.99 | -74.22 | 330.39 | 14.86 | 1.63 | 12.03 | 3.06 | 1.93 | 1.86 | 10.25 | 0.97 | 5.57 | -5.30 |
Last Updated: August 19, 2025, 8:35 pm
Below is a detailed analysis of the quarterly data for Cravatex Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.13 Cr.. The value appears to be declining and may need further review. It has decreased from 60.52 Cr. (Mar 2025) to 23.13 Cr., marking a decrease of 37.39 Cr..
- For Expenses, as of Jun 2025, the value is 29.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 60.01 Cr. (Mar 2025) to 29.24 Cr., marking a decrease of 30.77 Cr..
- For Operating Profit, as of Jun 2025, the value is -6.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.51 Cr. (Mar 2025) to -6.11 Cr., marking a decrease of 6.62 Cr..
- For OPM %, as of Jun 2025, the value is -26.42%. The value appears to be declining and may need further review. It has decreased from 0.84% (Mar 2025) to -26.42%, marking a decrease of 27.26%.
- For Other Income, as of Jun 2025, the value is 5.21 Cr.. The value appears strong and on an upward trend. It has increased from 2.09 Cr. (Mar 2025) to 5.21 Cr., marking an increase of 3.12 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 0.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.40 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.37 Cr.. The value appears to be declining and may need further review. It has decreased from 2.11 Cr. (Mar 2025) to -1.37 Cr., marking a decrease of 3.48 Cr..
- For Tax %, as of Jun 2025, the value is 0.73%. The value appears to be improving (decreasing) as expected. It has decreased from 31.75% (Mar 2025) to 0.73%, marking a decrease of 31.02%.
- For Net Profit, as of Jun 2025, the value is -1.37 Cr.. The value appears to be declining and may need further review. It has decreased from 1.44 Cr. (Mar 2025) to -1.37 Cr., marking a decrease of 2.81 Cr..
- For EPS in Rs, as of Jun 2025, the value is -5.30. The value appears to be declining and may need further review. It has decreased from 5.57 (Mar 2025) to -5.30, marking a decrease of 10.87.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 8:03 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 244 | 232 | 255 | 266 | 356 | 718 | 865 | 532 | 594 | 504 | 203 | 174 | 171 |
| Expenses | 230 | 218 | 249 | 271 | 361 | 694 | 843 | 543 | 592 | 533 | 210 | 175 | 177 |
| Operating Profit | 13 | 14 | 6 | -5 | -6 | 24 | 21 | -11 | 2 | -30 | -8 | -2 | -5 |
| OPM % | 5% | 6% | 2% | -2% | -2% | 3% | 2% | -2% | 0% | -6% | -4% | -1% | -3% |
| Other Income | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 13 | 10 | 118 | 16 | 10 | 12 |
| Interest | 8 | 10 | 13 | 11 | 5 | 6 | 14 | 15 | 14 | 14 | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 3 | 3 | 6 | 6 | 15 | 17 | 16 | 16 | 2 | 1 | 2 |
| Profit before tax | 7 | 3 | -7 | -15 | -12 | 17 | -2 | -30 | -19 | 58 | 6 | 6 | 4 |
| Tax % | 27% | 28% | 8% | -9% | 2% | 37% | 95% | 3% | 7% | -1% | 22% | 24% | |
| Net Profit | 5 | 2 | -8 | -14 | -12 | 11 | -5 | -31 | -20 | 59 | 5 | 5 | 3 |
| EPS in Rs | 18.88 | 9.25 | -30.65 | -53.67 | -47.75 | 41.25 | -18.23 | -118.45 | -76.97 | 228.04 | 18.69 | 18.69 | 11.49 |
| Dividend Payout % | 18% | 22% | 0% | 0% | -2% | 5% | -16% | -3% | -4% | 1% | 16% | 67% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -60.00% | -500.00% | -75.00% | 14.29% | 191.67% | -145.45% | -520.00% | 35.48% | 395.00% | -91.53% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -440.00% | 425.00% | 89.29% | 177.38% | -337.12% | -374.55% | 555.48% | 359.52% | -486.53% | 91.53% |
Cravatex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -27% |
| 3 Years: | -34% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | -39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 4% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -16% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:06 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 113 | 115 | 106 | 84 | 106 | 76 | 72 | 98 | 82 | 19 | 25 | 50 |
| Inventory Days | 87 | 124 | 124 | 84 | 53 | 60 | 49 | 85 | 84 | 29 | 28 | 40 |
| Days Payable | 61 | 66 | 71 | 65 | 89 | 16 | 25 | 23 | 36 | 21 | 25 | 43 |
| Cash Conversion Cycle | 139 | 173 | 159 | 102 | 70 | 120 | 95 | 160 | 130 | 27 | 28 | 47 |
| Working Capital Days | 35 | 42 | 20 | -4 | 40 | 27 | 10 | 24 | 29 | 16 | 15 | 19 |
| ROCE % | 15% | 12% | 5% | -3% | -6% | 18% | 6% | -6% | -2% | -24% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| Diluted EPS (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| Cash EPS (Rs.) | 24.40 | 25.97 | 290.52 | -13.62 | -50.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 411.83 | 382.02 | 357.42 | 98.58 | 181.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 411.83 | 382.02 | 357.42 | 98.58 | 181.71 |
| Revenue From Operations / Share (Rs.) | 672.41 | 784.12 | 1948.99 | 2299.88 | 2058.19 |
| PBDIT / Share (Rs.) | 31.94 | 32.66 | -69.16 | 43.74 | 7.78 |
| PBIT / Share (Rs.) | 26.22 | 25.37 | -131.63 | -19.60 | -59.71 |
| PBT / Share (Rs.) | 24.66 | 23.84 | 225.73 | -71.76 | -115.13 |
| Net Profit / Share (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| NP After MI And SOA / Share (Rs.) | 18.68 | 18.68 | 228.05 | -76.95 | -118.45 |
| PBDIT Margin (%) | 4.75 | 4.16 | -3.54 | 1.90 | 0.37 |
| PBIT Margin (%) | 3.90 | 3.23 | -6.75 | -0.85 | -2.90 |
| PBT Margin (%) | 3.66 | 3.04 | 11.58 | -3.12 | -5.59 |
| Net Profit Margin (%) | 2.77 | 2.38 | 11.70 | -3.34 | -5.75 |
| NP After MI And SOA Margin (%) | 2.77 | 2.38 | 11.70 | -3.34 | -5.75 |
| Return on Networth / Equity (%) | 4.53 | 4.89 | 63.80 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 6.18 | 6.42 | -36.18 | -3.18 | -9.16 |
| Return On Assets (%) | 3.43 | 3.87 | 43.12 | -5.45 | -7.94 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | -2.14 | -2.98 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | -3.36 | -5.47 |
| Asset Turnover Ratio (%) | 1.31 | 1.55 | 0.01 | 0.01 | 0.01 |
| Current Ratio (X) | 4.22 | 5.11 | 2.95 | 1.43 | 1.39 |
| Quick Ratio (X) | 3.86 | 4.64 | 2.27 | 0.97 | 1.00 |
| Inventory Turnover Ratio (X) | 15.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 20.39 | 21.30 | -1.34 | 0.83 | 0.14 |
| Interest Coverage Ratio (Post Tax) (X) | 12.93 | 13.18 | -2.50 | -0.47 | -1.14 |
| Enterprise Value (Cr.) | 13.09 | 36.92 | 26.37 | 297.69 | 268.76 |
| EV / Net Operating Revenue (X) | 0.07 | 0.18 | 0.05 | 0.50 | 0.50 |
| EV / EBITDA (X) | 1.59 | 4.37 | -1.48 | 26.34 | 133.65 |
| MarketCap / Net Operating Revenue (X) | 0.50 | 0.55 | 0.16 | 0.15 | 0.14 |
| Price / BV (X) | 0.83 | 1.14 | 0.89 | -1.87 | -2.65 |
| Price / Net Operating Revenue (X) | 0.50 | 0.55 | 0.16 | 0.15 | 0.14 |
| EarningsYield | 0.05 | 0.04 | 0.71 | -0.21 | -0.40 |
After reviewing the key financial ratios for Cravatex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.40. This value is within the healthy range. It has decreased from 25.97 (Mar 24) to 24.40, marking a decrease of 1.57.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 672.41. It has decreased from 784.12 (Mar 24) to 672.41, marking a decrease of 111.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 31.94. This value is within the healthy range. It has decreased from 32.66 (Mar 24) to 31.94, marking a decrease of 0.72.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.22. This value is within the healthy range. It has increased from 25.37 (Mar 24) to 26.22, marking an increase of 0.85.
- For PBT / Share (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.84 (Mar 24) to 24.66, marking an increase of 0.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For PBDIT Margin (%), as of Mar 25, the value is 4.75. This value is below the healthy minimum of 10. It has increased from 4.16 (Mar 24) to 4.75, marking an increase of 0.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from 3.23 (Mar 24) to 3.90, marking an increase of 0.67.
- For PBT Margin (%), as of Mar 25, the value is 3.66. This value is below the healthy minimum of 10. It has increased from 3.04 (Mar 24) to 3.66, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 5. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 8. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.53. This value is below the healthy minimum of 15. It has decreased from 4.89 (Mar 24) to 4.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.18. This value is below the healthy minimum of 10. It has decreased from 6.42 (Mar 24) to 6.18, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 3.43. This value is below the healthy minimum of 5. It has decreased from 3.87 (Mar 24) to 3.43, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.31. It has decreased from 1.55 (Mar 24) to 1.31, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 4.22. This value exceeds the healthy maximum of 3. It has decreased from 5.11 (Mar 24) to 4.22, marking a decrease of 0.89.
- For Quick Ratio (X), as of Mar 25, the value is 3.86. This value exceeds the healthy maximum of 2. It has decreased from 4.64 (Mar 24) to 3.86, marking a decrease of 0.78.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.69. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 15.69, marking an increase of 15.69.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.39. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 20.39, marking a decrease of 0.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 13.18 (Mar 24) to 12.93, marking a decrease of 0.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.09. It has decreased from 36.92 (Mar 24) to 13.09, marking a decrease of 23.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1. It has decreased from 0.18 (Mar 24) to 0.07, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 5. It has decreased from 4.37 (Mar 24) to 1.59, marking a decrease of 2.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.14 (Mar 24) to 0.83, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cravatex Ltd:
- Net Profit Margin: 2.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.18% (Industry Average ROCE: 15.44%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.53% (Industry Average ROE: 8.88%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.86
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.8 (Industry average Stock P/E: 101.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | 1st Floor, Godrej Bhavan, 4A Home Street Mumbai Maharashtra 400001 | investors@cravatex.com http://www.cravatex.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Batra | Chairman & Managing Director |
| Mr. Divakar G Kamath | Executive Director & CFO |
| Mr. Rohan Batra | Non Executive Director |
| Mr. Pheroza Jimmy Bilimoria | Independent Director |
| Mr. Satyan Shivkumar Israni | Independent Director |
| Mr. Nakul Toshniwal | Independent Director |
| Ms. Rina Suresh Deora | Independent Director |